Auxilium Pharmaceuticals Selected for Inclusion in the NASDAQ Biotech Index
14th Nov 2006, 16:38 GMT
Auxilium Pharmaceuticals announced that the Nasdaq Stock Market will add the Company to the NASDAQ Biotech Index effective with the opening of the market, 11/20/2006.
Auxilium Pharmaceuticals Selected for Inclusion in the NASDAQ Biotech Index related news:
- Auxilium added to NASDAQ's biotech index — bizjournals.com Health Care:Pharmaceuticals headlines
- Auxilium Pharmaceuticals Selected for Inclusion in the NASDAQ Biotechnology Index — PR Newswire: All Releases
- Genebase Systems Inc. and Genetrack Biolabs Inc.: DNA Technology Meets Web 2.0 in the Newest Tool for Tracking Your Ancestral Roots — Market Wire - Pharmaceuticals and Biotech
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions — Market Wire - Pharmaceuticals and Biotech
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits — Market Wire - Pharmaceuticals and Biotech
- Amazon Biotech, Inc: Amazon Biotech Inc. Announces Union Bless Herbal Products' Application for Amendment to Approved Import Drug License to Include Amazon Biotech as Approved Supplier — Market Wire - Pharmaceuticals and Biotech
- Inflazyme Pharmaceuticals Ltd.: Inflazyme Pharmaceuticals Ltd.: Shareholder Letter and Financial Results for the Quarter Ended September 30, 2006 — Market Wire - Pharmaceuticals and Biotech
- Mercury, BU team says biotech app cuts processing time to minutes — bizjournals.com Health Care:Pharmaceuticals headlines
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech — Market Wire - Pharmaceuticals and Biotech
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products — Market Wire - Pharmaceuticals and Biotech
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress